Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer

EU science hub. European commission's science and knowledge service. Available at: https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe. Harrison, 2013, Ra-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease, Cancer Manag Res, 5, 1, 10.2147/CMAR.S25537 Parker, 2013, Alpha emitter Ra-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 National Institute of Health and Care Excellence. Ra-223 dichloride for treating hormone relapsed prostate cancer with bone metastases. Technology Appraisal Guidance [TA412]. Published 28 September 2016. Available at: www.nice.org.uk/guidance/TA412/chapter/1-Recommendations. Yorkshire and Humber NHS clinical senate. Available at: www.yhsenate.nhs.uk. Piccirillo, 2004, Prognostic importance of comorbidity in a hospital based cancer registry, JAMA, 291, 2441, 10.1001/jama.291.20.2441 Wong, 2017, Factors associated with survival following Ra-223 treatment for metastatic castration-resistant prostate cancer, Clin Genitourin Cancer, 15, e969, 10.1016/j.clgc.2017.04.016 Hague, 2016, Clinical experience with Ra-223in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases, Ther Adv Urol, 8, 175, 10.1177/1756287216629870 Etchebehere, 2016, Factors affecting Ra223 therapy: clinical experience after 532 cycles from a single institution, Eur J Nucl Med Mol Imaging, 43, 8, 10.1007/s00259-015-3185-4 Saad, 2016, Analysis of overall survival by number of Ra-223 injections received in an international expanded access program (iEAP), J Clin Oncol, 34, S5082, 10.1200/JCO.2016.34.15_suppl.5082 Stolten, 2015, Parameters associated with 6 cycles of Ra-223 dichloride therapy in metastatic castrate resistant prostate cancer, Int J Radiat Oncol Biol Phys, 93, E196, 10.1016/j.ijrobp.2015.07.1047 O'Sullivan, 2015, Effects of concomitant use of abiraterone and/or enzalutamide with Ra-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP), Eur J Cancer, 51, S497, 10.1016/S0959-8049(16)31380-6 Templeton, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, Natl Cancer Inst, 106, 124, 10.1093/jnci/dju124 Conteduca, 2016, Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer, PLoS One, 11, e0158952, 10.1371/journal.pone.0158952 Boegemann, 2017, The role of the neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone, Int J Mol Sci, 18, 380, 10.3390/ijms18020380 Mehra, 2017, Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids, Clin Genitourin Cancer, 15, 678, 10.1016/j.clgc.2017.05.012 Lorente, 2015, Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use, Ann Oncol, 26, 750, 10.1093/annonc/mdu587